Rapid Nutrition (ALRPD) H1 2025 earnings summary

Executive summary

• Revenue for H1 2025 was AUD 113,125, down from AUD 276,051 year-over-year, reflecting a strategic shift to a direct-to-consumer subscription model.

• 642 new active subscriptions were secured, with a focus on recurring revenue and long-term brand loyalty.

• The company cleared all convertible debt, improved its cash position nearly tenfold to AUD 900,672, and increased net assets to AUD 1.65 million.

• Strategic expansion included a successful China launch and product innovation, with System LS selected for a large-scale U.S. clinical trial.

Financial highlights

• Trade receivables rose to AUD 893,423 from AUD 448,691, indicating a strong pipeline for H2 revenue.

• Operating cash burn reduced by 11% year-over-year.

• Gross profit for H1 2025 was AUD 59,583, down from AUD 100,316 in H1 2024.

• Net loss for H1 2025 was AUD 1,650,846, an improvement from a loss of AUD 1,986,167 in H1 2024.

• Cash and cash equivalents increased to AUD 900,672 from AUD 95,809 at December 2024.

Outlook and guidance

• Management expects significant sales uplift in Q3 and Q4, driven by major buying periods in Asia, new SKUs, and expanded distribution partnerships.

• All major product manufacturing is complete, with marketing budgets secured and inventory positioned for seasonal demand.

• The company anticipates compounding growth from its subscription model and international expansion.